Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

This phase II trial compares the effect of hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) when given in combination with cisplatin and brachytherapy in patients with stage IB3, II, or III cervical cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. CFRT delivers the total dose of radiation over the amount of time according to standard practice. HFRT delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. HFRT sh

Trial Details

NCT ID
NCT07276360
Phase
PHASE2
Sponsor
Uganda Cancer Institute
Status
RECRUITING
Cancer Type
Adenocarcinoma Cervical Cancer
Interventions
  • Hypofractionated Radiation Therapy
  • Conventional Fractionated Radiotherapy
  • Cisplatin
  • High-Dose Rate Brachytherapy
  • External Beam Radiotherapy Boost
  • Computed Tomography
Locations (sample)
  • Kampala, Kampala, Uganda|0.31628,32.58219

Key Eligibility Criteria

  • Females aged 18 years or older
  • Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix without prior treatment
  • Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3, IIA, IIB, IIIA, IIIB, or IIIC
  • Able to provide written informed consent in English, Luganda, Runyankole, or Lango

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Cervical Cancer Trials on Trialify →